| RYR2 altered in cohorts of …ALTERED_INderived29 of 29show fewer |
|---|
| → altered in cohorts of | Breast Invasive Carcinoma, NOS 800 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| → altered in cohorts of | Lung Adenocarcinoma 413 / 573 cases (72 %) · ssm · TCGA-LUAD · largest of 11 cohorts | — | — | Lung Adenocarcinoma | 11 | Observed | gdc | graph → |
| → altered in cohorts of | Skin Basal Cell Carcinoma 72 / 126 cases (57 %) · ssm · bcc_unige_2016 | — | — | Skin Basal Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Endometrial Carcinoma 291 / 559 cases (52 %) · ssm · TCGA-UCEC · largest of 5 cohorts | — | — | Endometrial Carcinoma | 5 | Observed | gdc | graph → |
| → altered in cohorts of | Lung Small Cell Carcinoma 54 / 120 cases (45 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Lung Squamous Cell Carcinoma 192 / 484 cases (40 %) · ssm · lusc_tcga_pan_can_atlas_2018 · largest of 6 cohorts | — | — | Lung Squamous Cell Carcinoma | 6 | Observed | cbioportal | graph → |
| → altered in cohorts of | Lung Non-Small Cell Carcinoma 448 / 1,144 cases (39 %) · ssm · nsclc_tcga_broad_2016 · largest of 3 cohorts | — | — | Lung Non-Small Cell Carcinoma | 3 | Observed | cbioportal | graph → |
| → altered in cohorts of | Skin Squamous Cell Carcinoma 26 / 83 cases (31 %) · ssm · cscc_ucsf_2021 · largest of 3 cohorts | — | — | Skin Squamous Cell Carcinoma | 3 | Observed | cbioportal | graph → |
| → altered in cohorts of | Cutaneous Melanoma 107 / 469 cases (23 %) · ssm · skcm_tcga_gdc · largest of 5 cohorts | — | — | Cutaneous Melanoma | 5 | Observed | cbioportal | graph → |
| → altered in cohorts of | Renal Cell Carcinoma 34 / 158 cases (22 %) · ssm · rcc_iatlas_immotion150_2018 | — | — | Renal Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Thymoma 25 / 124 cases (20 %) · ssm · TCGA-THYM | — | — | Thymoma | 1 | Observed | gdc | graph → |
| → altered in cohorts of | Colon Adenocarcinoma 86 / 429 cases (20 %) · ssm · coad_tcga_gdc · largest of 3 cohorts | — | — | Colon Adenocarcinoma | 3 | Observed | cbioportal | graph → |
| → altered in cohorts of | Gastroesophageal Junction Adenocarcinoma 98 / 518 cases (19 %) · ssm · stes_tcga_pub | — | — | Gastroesophageal Junction Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Endometrial Endometrioid Adenocarcinoma 43 / 247 cases (17 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Esophageal Adenocarcinoma 31 / 185 cases (17 %) · ssm · esca_tcga · largest of 3 cohorts | — | — | Esophageal Adenocarcinoma | 3 | Observed | cbioportal | graph → |
| → altered in cohorts of | Rectal Adenocarcinoma 25 / 155 cases (16 %) · ssm · read_tcga_gdc | — | — | Rectal Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Gastric Adenocarcinoma 77 / 478 cases (16 %) · ssm · stad_tcga · largest of 4 cohorts | — | — | Gastric Adenocarcinoma | 4 | Observed | cbioportal | graph → |
| → altered in cohorts of | Bladder Urothelial Carcinoma 64 / 474 cases (14 %) · ssm · blca_msk_tcga_2020 · largest of 7 cohorts | — | — | Bladder Urothelial Carcinoma | 7 | Observed | cbioportal | graph → |
| → altered in cohorts of | Cervical Squamous Cell Carcinoma 35 / 291 cases (12 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 3 cohorts | — | — | Cervical Squamous Cell Carcinoma | 3 | Observed | cbioportal | graph → |
| → altered in cohorts of | Head and Neck Squamous Cell Carcinoma 60 / 515 cases (12 %) · ssm · hnsc_tcga_pan_can_atlas_2018 · largest of 4 cohorts | — | — | Head and Neck Squamous Cell Carcinoma | 4 | Observed | cbioportal | graph → |
| → altered in cohorts of | Hepatocellular Carcinoma 57 / 494 cases (12 %) · ssm · hcc_clca_2024 · largest of 5 cohorts | — | — | Hepatocellular Carcinoma | 5 | Observed | cbioportal | graph → |
| → altered in cohorts of | Colorectal Adenocarcinoma 112 / 1,015 cases (11 %) · ssm · crc_sysucc_2022 · largest of 5 cohorts | — | — | Colorectal Adenocarcinoma | 5 | Observed | cbioportal | graph → |
| → altered in cohorts of | B-Cell Non-Hodgkin Lymphoma 64 / 755 cases (8.5 %) · ssm · mbn_mdacc_2013 · largest of 2 cohorts | — | — | B-Cell Non-Hodgkin Lymphoma | 2 | Observed | cbioportal | graph → |
| → altered in cohorts of | Multiple Myeloma 81 / 961 cases (8.4 %) · ssm · MMRF-COMMPASS | — | — | Multiple Myeloma | 1 | Observed | gdc | graph → |
| → altered in cohorts of | Cholangiocarcinoma 32 / 417 cases (7.7 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Invasive Breast Carcinoma 161 / 2,433 cases (6.6 %) · ssm · brca_metabric · largest of 6 cohorts | — | — | Invasive Breast Carcinoma | 6 | Observed | cbioportal | graph → |
| → altered in cohorts of | Diffuse Glioma 46 / 812 cases (5.7 %) · ssm · lgggbm_tcga_pub · largest of 7 cohorts | — | — | Diffuse Glioma | 7 | Observed | cbioportal | graph → |
| → altered in cohorts of | Prostate Adenocarcinoma 25 / 444 cases (5.6 %) · ssm · prad_su2c_2019 | — | — | Prostate Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | High-Grade Serous Ovarian Cancer 28 / 523 cases (5.4 %) · ssm · ov_tcga_pan_can_atlas_2018 · largest of 2 cohorts | — | — | High-Grade Serous Ovarian Cancer | 2 | Observed | cbioportal | graph → |